Clinical implications of detectable baseline hepatitis C virus-genotype 1 NS3/4A-protease variants on the efficacy of boceprevir combined with peginterferon/ribavirin

Open Forum Infectious Diseases

Volumn 1, Issue 2, 2014, Pages

  Howe, John A ^a   Long, Jianmin ^a   Black, Stuart ^a   Chase, Robert ^a   McMonagle, Patricia ^a   Curry, Stephanie ^a   Thompson, Seth ^a   DiNubile, Mark J ^a   Howe, Anita Y M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Boceprevir; Hepatitis C genotype 1; RAVs; Resistance associated variants

Indexed keywords

BOCEPREVIR; HEPACIVIRIN; INTERFERON; INTERLEUKIN 28; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; DRUG EFFICACY; EC50; FEMALE; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84976260940     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofu078     Document Type: Article

References (28)

1. Welsch C, Zeuzem S. Clinical relevance of HCV antiviral drug resistance. Curr Opin Virol 2012; 2:651-5.
2. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132:1767-77.
3. Gambarin-Gelwan M, Jacobson IM. Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors. Curr Gastroenterol Rep 2012; 14:47-54.
4. HCV DrAG Phenotype and Sequence Analysis Working Group. Ann Forum Collab HIV Res. Available at: http://www.idsociety.org/up loadedFiles/IDSA/Hepatitis_C/For_IDSA_Members/ForumforCollab orativeHIV-ClinicallyRelevantHCVDrug.pdf. Accessed 29 January 2014.
5. Barnard RJ, Howe JA, Ogert RA, et al. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology 2013; 444:329-36.
6. Sullivan JC, De Meyer S, Bartels DJ, et al. Evolution of treatmentemergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis 2013; 57:221-9.
7. Romano KP, Ali A, Aydin C, et al. The molecular basis of drug resistance against hepatitis C virus NS3/4a protease inhibitors. PLoS Pathog 2012; 8:1-15.
8. Ribeiro RM, Li H,Wang S, et al. Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog 2012; 8:e1002881.
9. Vallet S, Viron F, Henquell C, et al. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5. Antivir Ther 2011; 16:1093-102.
10. Vicenti I, Rosi A, Saladini F, et al. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. J Antimicrob Chemother 2012; 67:984-7.
11. Bartels DJ, Sullivan JC, Zhang EZ, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol 2013; 87: 1544-53.
12. Rong L, Dahari H, Ribeiro RM, et al. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2010; 2:30ra32.
13. Cento V, Mirabelli C, Salpini R, et al. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One 2012; 7:e39652.
14. Hara K, Rivera MM, Koh C, et al. Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection? J Infect Dis 2014; 209:38-45.
15. Akuta N, Suzuki F, Fukushima T, et al. Utility of detection of telaprevirresistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection. J Clin Microbiol 2014; 52:193-200.
16. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-206.
17. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-17.
18. Kwo P, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376:705-16.
19. Flamm SL, Lawitz E, Jacobson I, et al. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol 2013; 11:81-7.
20. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13:597-605.
21. Poordad F, Lawitz E, Reddy R, et al. Effects of ribavirin dose reduction versus erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection-a randomized trial. Gastroenterology 2013; 145:1035-44.
22. Leitner T, Halapi E, Scarlatti G, et al. Analysis of heterogeneous viral populations by direct DNA sequencing. Biotechniques 1993; 15:120-7.
23. Koletzki D, Pattery T, Fevery B, et al. Amplification and sequencing of the hepatitis C virus NS3/4a protease and the NS5b polymerase regions for genotypic resistance detection of clinical isolates of subtypes 1a and 1b. Methods Mol Biol 2013; 1030:137-49.
24. Suzuki F, Sezaki H, Akuta N, et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol 2012; 54:352-4.
25. Wu S, Kanda T, Nakamoto S, et al. Hepatitis C virus protease inhibitorresistance mutations: our experience and review. World J Gastroenterol 2013; 19:8940-8.
26. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013; 368:1907-17.
27. AASLD, IDSA, IAS-USA. Recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org. Accessed 24 April 2014.
28. Jayasekera CR, Barry M, Roberts LR, Nguyen MH. Treating hepatitis C in lower-income countries. N Engl J Med 2014; 370:1869-71.